secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2022-01-03T23:59:59+00:00
Accession:  0001564590-22-000016
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid licenses KCC2 activator library from AstraZeneca; $5M cash + $7.5M stock upfront
--------------------------------------------------------------------------------

- Exclusive worldwide license for early-stage small molecules targeting KCC2, including lead OV350.
- Upfront consideration: $5M cash + $7.5M in Ovid common stock (2,272,727 shares).
- Milestones up to $8M clinical, $45M regulatory, $150M commercial; royalties single-digit to 10%.
- AstraZeneca retains right of first negotiation at proof of clinical efficacy for strategic collaboration.
- OV350 shows in-vitro/in-vivo proof of concept in resistant epilepsy; Ovid to collaborate with Drs. Moss, Maguire.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000156459022000016/0001564590-22-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000156459022000016/ovid-8k_20211230.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer